FLT3 Inhibitor Highly Active in Newly Diagnosed Acute Myeloid Leukemia

(MedPage Today) -- Patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) had a high response rate and prolonged event-free survival (EFS) following treatment with an investigational FLT3 inhibitor and chemotherapy, a preliminary...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news